Lenti-HPV-07 / TheraVectys - LARVOL DELTA

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer (clinicaltrials.gov) - P1/2 | N=72 | Recruiting | Sponsor: Theravectys S.A. | Trial primary completion date: Dec 2025 ➔ Jun 2026

IO biomarker • Trial primary completion date • Cervical Cancer • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer (clinicaltrials.gov) - P1/2 | N=72 | Recruiting | Sponsor: Theravectys S.A. | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2024 ➔ Aug 2024

Enrollment open • Trial initiation date • Viral vector • Cervical Cancer • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Human Papillomavirus (HPV)-induced Cancers: First Patient Enrolled in Phase I/IIa Clinical Trial for Lenti-HPV-07, the TheraVectys’ Therapeutic Vaccine Candidate Against Oropharyngeal and Cervical Cancers (Businesswire) - "TheraVectys...announces that the first patient has been enrolled in the Phase I/IIa clinical trial evaluating the onco-therapeutic vaccine Lenti-HPV-07 for the treatment of human papillomavirus (HPV)-induced cancers....This study will include 36 patients in a dose-escalation protocol conducted at several cancer centers in the United States. Selection and inclusion of these patients are already underway."

Trial status • Cervical Cancer • Gynecologic Cancers • Oncology • Oropharyngeal Cancer • Solid Tumor

T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector. (PubMed, NPJ Vaccines) - "Here, we first established that anti-vector immunity induced by Lenti-HPV-07 prime has no impact on the efficacy of a homologous boost to amplify anti-HPV T-cell immunity. We then demonstrated that the effector functions of such Lenti-HPV-07-induced T cells synergize with anti-checkpoint inhibitory treatments by systemic administration of anti-TIM3 or anti-NKG2A monoclonal antibodies. While Lenti-HPV-07 is about to enter a Phase I/IIa clinical trial, these results will help better elucidate its mode of action in immunotherapy against established HPV-mediated malignancies."

Journal • Viral vector • Oncology • CD8 • KLRC1

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer (clinicaltrials.gov) - P1/2 | N=72 | Not yet recruiting | Sponsor: Theravectys S.A.

New P1/2 trial • Viral vector • Cervical Cancer • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck